ArticleNMR in biomedicine2025
A Cardiac Magnetic Resonance-Based Risk Stratification for Life-Threatening Ventricular Tachyarrhythmias in Heart Failure: The SNE
Article in NMR in biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Narrative Review of Risk Assessment Approaches for Implantable Defibrillator Therapy to Prevent Sudden Cardiac Death in Acute Myocardial Infarction.Cardiology research and practice · 2026Review
- A Cardiac Magnetic Resonance-Based Risk Stratification for Life-Threatening Ventricular Tachyarrhythmias in Heart Failure: The SNENMR in biomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Risk stratification for sudden cardiac death (SCD) mainly relies on severely reduced left ventricular ejection fraction (LVEF), but its poor predictive efficacy fails to meet clinical needs. Myocardial scarring identified using cardiac magnetic resonance (CMR) imaging has emerged as a potent risk indicator for SCD and life-threatening ventricular tachyarrhythmias (LTVTA). This study aimed to develop a risk prediction score for SCD and ventricular tachyarrhythmias in symptomatic heart failure. Consecutive patients with nonischemic heart failure undergoing CMR were monitored from 2018 to 2024. A risk stratification score was developed by integrating CMR parameters with clinical variables. Among the 199 patients, the median LVEF was 32.7%, and the average age was 50.3 ± 15.2 years. During a median observation period of 3 years, 21 (10.5%) patients experienced LTVTA. Among multiple CMR parameters, the presence of late gadolinium enhancement (LGE) was the only independent risk factor for LTVTA. The final risk scoring model comprised the presence of LGE (hazard ratio, 10.68; p = 0.023), assigned a score of 2; syncope (hazard ratio, 4.41; p = 0.003), assigned a score of 1; and nonsustained ventricular tachycardia (hazard ratio, 3.82; p = 0.004), assigned a score of 1. A total score of ≥ 3 was considered high risk. Harrell's C-statistic was 0.814 in the derivation cohort and 0.785 in the external validation cohort. The 3-year cumulative risks for the low- and high-risk groups were 3.6% and 32.8%, respectively. Among CMR parameters, the presence of LGE was identified as the sole independent and strong risk marker of LTVTA. The novel scoring model may assist in the preliminary screening of patients with symptomatic heart failure with a potentially elevated risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.